## Erik Johnsen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7560190/publications.pdf

Version: 2024-02-01

73 papers 1,266 citations

20 h-index 395702 33 g-index

74 all docs

74 docs citations

times ranked

74

2294 citing authors

#	Article	IF	CITATIONS
1	Lower circulating neuron-specific enolase concentrations in adults and adolescents with severe mental illness. Psychological Medicine, 2023, 53, 1479-1488.	4.5	6
2	Neural Activation in the Ventromedial Prefrontal Cortex Precedes Conscious Experience of Being in or out of a Transient Hallucinatory State. Schizophrenia Bulletin, 2023, 49, S58-S67.	4.3	7
3	Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. Schizophrenia Bulletin, 2022, 48, 37-46.	4.3	10
4	Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain, Behavior, and Immunity, 2022, 99, 299-306.	4.1	33
5	Association between C-reactive protein levels and antipsychotic treatment during 12Âmonths follow-up period after acute psychosis. Schizophrenia Research, 2022, 241, 174-183.	2.0	3
6	Quality of clinical management of cardiometabolic risk factors in patients with severe mental illness in a specialist mental health care setting. Nordic Journal of Psychiatry, 2022, 76, 602-609.	1.3	5
7	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatrica, 2022, 34, 282-288.	2.1	2
8	Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness. World Journal of Psychiatry, 2022, 12, 521-532.	2.7	1
9	Negative valence of hallucinatory voices as predictor of cortical glutamatergic metabolite levels in schizophrenia patients. Brain and Behavior, 2022, 12, e32446.	2.2	3
10	Turnover of IPS employment specialists: Rates and predictors. Journal of Vocational Rehabilitation, 2022, 57, 23-32.	0.9	2
11	Mapping psychoticâ€like experiences: Results from an online survey. Scandinavian Journal of Psychology, 2021, 62, 237-248.	1.5	11
12	Pragmatic antipsychotics trialâ€"caution in interpretation â€" Authors' reply. Lancet Psychiatry,the, 2021, 8, 101.	7.4	1
13	Glutamate- and GABA-Modulated Connectivity in Auditory Hallucinationsâ€"A Combined Resting State fMRI and MR Spectroscopy Study. Frontiers in Psychiatry, 2021, 12, 643564.	2.6	7
14	The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. Substance Use and Misuse, 2021, 56, 1880-1891.	1.4	0
15	Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophrenia, 2021, 7, 39.	3.6	35
16	Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study. Schizophrenia Research, 2021, 235, 29-35.	2.0	12
17	Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT. Schizophrenia Research: Cognition, 2021, 26, 100204.	1.3	2
18	White Matter Microstructural Differences between Hallucinating and Non-Hallucinating Schizophrenia Spectrum Patients. Diagnostics, 2021, 11, 139.	2.6	6

#	Article	IF	CITATIONS
19	The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal study. Brain, Behavior, & Immunity - Health, 2021, 18, 100392.	2.5	6
20	Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 633-642.	4.3	23
21	T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS. Schizophrenia Bulletin, 2020, 46, S237-S237.	4.3	O
22	T206. ANTIPSYCHOTIC EFFECTIVENESS FOCUSING ON INSIGHT. Schizophrenia Bulletin, 2020, 46, S310-S311.	4.3	0
23	M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE. Schizophrenia Bulletin, 2020, 46, S149-S150.	4.3	O
24	M47. AKATHISIA AND ATYPICAL ANTIPSYCHOTICS: EXPLORING ASSOCIATIONS TO SUICIDALITY AND AGITATION. Schizophrenia Bulletin, 2020, 46, S151-S152.	4.3	2
25	M140. WHAT HAPPENS IN THE BRAIN A FEW SECONDS BEFORE THE ONSET AND OFFSET OF AN HALLUCINATORY EPISODE?. Schizophrenia Bulletin, 2020, 46, S188-S189.	4.3	O
26	M146. NEUROCHEMICAL MODULATION OF AUDITORY CORTEX FUNCTIONAL CONNECTIVITY IN PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS. Schizophrenia Bulletin, 2020, 46, S191-S191.	4.3	0
27	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.5	28
28	Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt) Tj ETQq0 0 0 rg	gBT /Overlo	ogk 10 Tf 50
29	Hallucinating schizophrenia patients have longer left arcuate fasciculus fiber tracks: a DTI tractography study. Psychiatry Research - Neuroimaging, 2020, 302, 111088.	1.8	9
30	Different response patterns in hallucinations and delusions to antipsychotic treatment. Nordic Journal of Psychiatry, 2020, 74, 497-504.	1.3	3
31	Elderly patients with no previous psychiatric history: suicidality and other factors relating to psychiatric acute admissions. BJPsych Open, 2020, 6, e63.	0.7	1
32	Dynamic Functional Connectivity Patterns in Schizophrenia and the Relationship With Hallucinations. Frontiers in Psychiatry, 2020, 11, 227.	2.6	36
33	T134. THE ROLE OF THE DEFAULT MODE NETWORK IN SCHIZOPHRENIA AND AUDITORY VERBAL HALLUCINATIONS – AN INVESTIGATION OF DYNAMIC FMRI RESTING STATE CONNECTIVITY. Schizophrenia Bulletin, 2020, 46, S281-S282.	4.3	1
34	Predictors of treatment satisfaction in antipsychotic-na $\tilde{A}$ -ve and previously medicated patients with acute-phase psychosis. Nordic Journal of Psychiatry, 2019, 73, 349-356.	1.3	3
35	Supported accommodation for people with schizophrenia. Nordic Journal of Psychiatry, 2019, 73, 211-218.	1.3	3
36	Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms. Frontiers in Psychiatry, 2019, 10, 695.	2.6	13

#	Article	IF	Citations
37	S2. CHILDHOOD TRAUMA SUBTYPES IN RELATION TO COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS. Schizophrenia Bulletin, 2019, 45, S306-S306.	4.3	O
38	The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study. Nordic Journal of Psychiatry, 2019, 73, 281-287.	1.3	6
39	Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. British Journal of Clinical Pharmacology, 2019, 85, 1598-1606.	2.4	38
40	Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatrica, 2019, 31, 36-45.	2.1	15
41	Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. Psychiatry Research, 2018, 261, 481-487.	3.3	20
42	The Beliefs about Voices Questionnaire – Revised: A factor structure from 450 participants. Psychiatry Research, 2018, 259, 95-103.	3.3	19
43	S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAÃ VE AND PREVIOUSLY MEDICATED PATIENTS. Schizophrenia Bulletin, 2018, 44, S346-S346.	4.3	O
44	S87. THE INITIAL CHANGE IN THE SERUM LEVEL OF C-REACTIVE PROTEIN IN ACUTE PSYCHOSIS IS ASSOCIATED WITH COGNITIVE PERFORMANCE IN LATER PHASES. Schizophrenia Bulletin, 2018, 44, S358-S359.	4.3	0
45	S3. CHILDHOOD TRAUMA AND COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS: EFFECT OF FREQUENCY AND TYPE OF CHILDHOOD TRAUMA. Schizophrenia Bulletin, 2018, 44, S324-S325.	4.3	O
46	Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophrenia, 2018, 4, 22.	3.6	53
47	F108. PSYCHOTIC EXPERIENCES IN A NORWEGIAN SAMPLE - TENTATIVE RESULTS OF A QUESTIONNAIRE VALIDATION. Schizophrenia Bulletin, 2018, 44, S261-S262.	4.3	O
48	Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics. Frontiers in Psychiatry, 2018, 9, 753.	2.6	58
49	The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry, 2016, 16, 60.	2.6	54
50	Patient satisfaction after acute admission for psychosis. Nordic Journal of Psychiatry, 2016, 70, 321-328.	1.3	23
51	Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119). Schizophrenia Research, 2016, 170, 217-221.	2.0	47
52	The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement. PLoS ONE, 2016, 11, e0167390.	2.5	18
53	Influence of different second generation antipsychotics on the QTc interval: A pragmatic study. World Journal of Psychiatry, 2016, 6, 442.	2.7	11
54	Borderline Personality Disorder and Posttraumatic Stress Disorder at Psychiatric Discharge Predict General Hospital Admission for Selfâ€Harm. Journal of Traumatic Stress, 2015, 28, 556-562.	1.8	14

#	Article	IF	Citations
55	Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study. Schizophrenia Research, 2015, 161, 252-260.	2.0	55
56	A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation. Frontiers in Psychiatry, 2014, 5, 11.	2.6	35
57	Cognitive changes in patients with acute phase psychosisâ€"Effects of illicit drug use. Psychiatry Research, 2014, 220, 818-824.	3.3	9
58	The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Frontiers in Psychiatry, 2014, 5, 159.	2.6	30
59	Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia. NeuroImage: Clinical, 2014, 4, 576-584.	2.7	53
60	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.7	152
61	Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies. Therapeutic Advances in Psychopharmacology, 2014, 4, 228-239.	2.7	18
62	The influence of glutamatergic antagonism on motor variability, and comparison to findings in schizophrenia patients. Acta Neuropsychiatrica, 2013, 25, 105-112.	2.1	6
63	Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. BMC Psychiatry, 2013, 13, 241.	2.6	10
64	QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics. Schizophrenia Research and Treatment, 2013, 2013, 1-7.	1.5	7
65	Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research. Expert Review of Neurotherapeutics, 2013, 13, 23-36.	2.8	9
66	Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease, 2012, 3, 287-300.	2.5	11
67	Sexual Dysfunction and Hyperprolactinemia in Male Psychotic Inpatients: A Cross-Sectional Study. Advances in Urology, 2011, 2011, 1-6.	1.3	11
68	Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. Nordic Journal of Psychiatry, 2011, 65, 192-202.	1.3	7
69	Review: metabolic side effects of second-generation antipsychotics. Evidence-Based Mental Health, 2011, 14, 47-47.	4.5	3
70	Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry, 2010, 10, 26.	2.6	53
71	Review: second generation antipsychotics are a heterogeneous drug class. Evidence-Based Mental Health, 2009, 12, 90-90.	<b>4.</b> 5	1
72	Effectiveness of second generation antipsychotics: A systematic review of randomized trials. BMC Psychiatry, 2008, 8, 31.	2.6	67

## Erik Johnsen

#	Article	IF	CITATIONS
73	Antipsychotic-Induced Hyperprolactinemia. Journal of Clinical Psychopharmacology, 2008, 28, 686-690.	1.4	41